CCR7 and myeloid sarcoma: The proportion of CD4+CCR7+ (T3) sub-cluster was significantly reduced in FTY-treated MS patients, while the proportion of CD4-CD8-CCR7- double negative (DN) sub-clusters (T7 and T9) was found to be increased (Fig. 5C).